August 9, 2016, Vol 316, No. 6, Pages 563-678

In This Issue of JAMA

Highlights

Abstract Full Text

free access has audio

JAMA. 2016;316(6):563-565. doi:10.1001/jama.2015.14419

Audio Editors' Summary: Stroke prevention during TAVR, lipid screening in children and adolescents, clinical manifestations of CKD in diabetes, and more

Original Investigation

Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial

Stephan Haussig, MD; Norman Mangner, MD; Michael G. Dwyer, MD; et al.

Abstract Full Text

free access has multimedia has audio

JAMA. 2016;316(6):592-601. doi:10.1001/jama.2016.10302

This randomized clinical trial compares the effects of use vs nonuse of a cerebral embolic protection device during transcatheter aortic valve implantation (TAVI) on MRI-detected brain lesions in patients with severe aortic stenosis undergoing TAVI.

Audio Author Interview: Cerebral Protection Device Effects on Brain Lesions After TAVI

Editorial
Improving Outcomes From Transcatheter Aortic Valve Implantation: Protecting the Brain From the Heart
Steven R. Messé, MD; Michael J. Mack, MD

Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014

Maryam Afkarian, MD, PhD; Leila R. Zelnick, PhD; Yoshio N. Hall, MD; et al.

Abstract Full Text

free access

JAMA. 2016;316(6):602-610. doi:10.1001/jama.2016.10924

This study uses National Health and Nutrition Examination Survey data from 1988 through 2014 to characterize clinical manifestations of diabetic kidney disease in US adults.

Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis

Tetsuya Isayama, MD, MSc; Hiroko Iwami, MD; Sarah McDonald, MD, FRCSC, MSc; et al.

Abstract Full Text

free access

JAMA. 2016;316(6):611-624. doi:10.1001/jama.2016.10708

This meta-analysis summarizes the comparative effects of mortality and BPD ventilation strategies delivered within 24 hours of birth to neonates younger than 33 weeks’ gestational age who had not been intubated.

Research Letter

Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy

Sean D. Pokorney, MD, MBA; DaJuanicia N. Simon, MS; Laine Thomas, PhD; et al.

Abstract Full Text

free access

JAMA. 2016;316(6):661-663. doi:10.1001/jama.2016.9356

This cohort study uses data from an atrial fibrillation registry to describe the proportion of patients on warfarin who had stable INR values over an 18-month period.

US Preventive Services Task Force

Recommendation Statement

Screening for Lipid Disorders in Children and Adolescents: US Preventive Services Task Force Recommendation Statement

US Preventive Services Task Force

Abstract Full Text

free access has audio

JAMA. 2016;316(6):625-633. doi:10.1001/jama.2016.9852

This Recommendation Statement from the US Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger.

Audio Author Interview: USPSTF Recommendation: Screening for Lipid Disorders in Youth

Editorial
Lipid Screening in Children and Adolescents
Elaine M. Urbina, MD, MS; Sarah D. de Ferranti, MD, MPH
On the US Preventive Services Task Force Statement on Screening for Lipid Disorders in Children and Adolescents: One Step Forward and 2 Steps Sideways
Stephen R. Daniels, MD, PhD
Lipid Screening in Children: Low-Value Care
Thomas B. Newman, MD, MPH; Alan R. Schroeder, MD; Mark J. Pletcher, MD, MPH
Why Cholesterol Testing in Children and Adolescents Matters
Samuel S. Gidding, MD

Evidence Report

Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force

Paula Lozano, MD, MPH; Nora B. Henrikson, PhD, MPH; Caitlin C. Morrison, MPH; et al.

Abstract Full Text

free access

JAMA. 2016;316(6):634-644. doi:10.1001/jama.2016.6423

This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia summarizes published evidence about the benefits and harms of screening.

Editorial
Lipid Screening in Children and Adolescents
Elaine M. Urbina, MD, MS; Sarah D. de Ferranti, MD, MPH
On the US Preventive Services Task Force Statement on Screening for Lipid Disorders in Children and Adolescents: One Step Forward and 2 Steps Sideways
Stephen R. Daniels, MD, PhD
Lipid Screening in Children: Low-Value Care
Thomas B. Newman, MD, MPH; Alan R. Schroeder, MD; Mark J. Pletcher, MD, MPH
Why Cholesterol Testing in Children and Adolescents Matters
Samuel S. Gidding, MD

Evidence Report

Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force

Paula Lozano, MD, MPH; Nora B. Henrikson, PhD, MPH; John Dunn, MD, MPH; et al.

Abstract Full Text

free access

JAMA. 2016;316(6):645-655. doi:10.1001/jama.2016.6176

This systematic review to support the 2016 update of the US Preventive Services Task Force Recommendation Statement on screening for lipid disorders in children and adolescents summarizes published evidence about the effectiveness of routine screening, accuracy of screening tests and strategies, and potential screening harms.

Editorial
Lipid Screening in Children and Adolescents
Elaine M. Urbina, MD, MS; Sarah D. de Ferranti, MD, MPH
On the US Preventive Services Task Force Statement on Screening for Lipid Disorders in Children and Adolescents: One Step Forward and 2 Steps Sideways
Stephen R. Daniels, MD, PhD
Lipid Screening in Children: Low-Value Care
Thomas B. Newman, MD, MPH; Alan R. Schroeder, MD; Mark J. Pletcher, MD, MPH
Why Cholesterol Testing in Children and Adolescents Matters
Samuel S. Gidding, MD

Viewpoint

Medical Board Expectations for Physicians Recommending Marijuana

Humayun J. Chaudhry, DO, MS; Arthur S. Hengerer, MD; Gregory B. Snyder, MD

Abstract Full Text

JAMA. 2016;316(6):577-578. doi:10.1001/jama.2016.7741

This Viewpoint examines physicians caught between permissive local statutes and prohibitive federal regulations regarding use of marijuana and summarizes recommendations about marijuana for patient care from the agencies authorized to protect the public.

Sodium Reduction—Saving Lives by Putting Choice Into Consumers’ Hands

Thomas R. Frieden, MD, MPH

Abstract Full Text

JAMA. 2016;316(6):579-580. doi:10.1001/jama.2016.7992

In this Viewpoint, CDC Director Thomas Frieden advocates for proposed FDA guidelines that set targets for the reduction of sodium in the US food supply.

Strategies for Health System Innovation After Gobeille v Liberty Mutual Insurance Company

Sean E. Bland, JD; Jeffrey S. Crowley, MPH; Lawrence O. Gostin, JD

Abstract Full Text

JAMA. 2016;316(6):581-582. doi:10.1001/jama.2016.8293

This Viewpoint proposes strategies US states might use to leverage electronic health data to inform policy making in the wake of Gobeille v Liberty Mutual Insurance Company, the Supreme Court decision barring states from requiring that health plans transmit their data to an all-payers claims database.

The Revised Nutrition Facts Label: A Step Forward and More Room for Improvement

Vasanti S. Malik, ScD; Walter C. Willett, MD, DrPH; Frank B. Hu, MD, PhD

Abstract Full Text

JAMA. 2016;316(6):583-584. doi:10.1001/jama.2016.8005

This Viewpoint reviews changes made in 2016 by the US Food and Drug Administration to the content and design of US food nutrition labels.

A Piece of My Mind

It’s Rough Out There for Us

Michael D. Stillman, MD; Steve R. Williams, MD

Abstract Full Text

JAMA. 2016;316(6):585-586. doi:10.1001/jama.2016.4460

Editorial

Improving Outcomes From Transcatheter Aortic Valve Implantation: Protecting the Brain From the Heart

Steven R. Messé, MD; Michael J. Mack, MD

Abstract Full Text

JAMA. 2016;316(6):587-588. doi:10.1001/jama.2016.10316

Lipid Screening in Children and Adolescents

Elaine M. Urbina, MD, MS; Sarah D. de Ferranti, MD, MPH

Abstract Full Text

JAMA. 2016;316(6):589-591. doi:10.1001/jama.2016.9671

Editorial
On the US Preventive Services Task Force Statement on Screening for Lipid Disorders in Children and Adolescents: One Step Forward and 2 Steps Sideways
Stephen R. Daniels, MD, PhD
Lipid Screening in Children: Low-Value Care
Thomas B. Newman, MD, MPH; Alan R. Schroeder, MD; Mark J. Pletcher, MD, MPH
Why Cholesterol Testing in Children and Adolescents Matters
Samuel S. Gidding, MD

From the JAMA Network

The Controversial Issue of Euthanasia in Patients With Psychiatric Illness

Emilie Olié, MD, PhD; Philippe Courtet, MD, PhD

Abstract Full Text

JAMA. 2016;316(6):656-657. doi:10.1001/jama.2016.9883

This commentary discusses a study published in JAMA Psychiatry that investigated the characteristics of patients receiving euthanasia or assisted suicide for psychiatric conditions and how the practice is regulated in the Netherlands.

JAMA Clinical Guidelines Synopsis

Primary Prevention of Stroke

Nathaniel Steiger, MD; Adam S. Cifu, MD

Abstract Full Text

JAMA. 2016;316(6):658-659. doi:10.1001/jama.2016.5529

This JAMA Clinical Guidelines Synopsis summarizes the American Heart Association/American Stroke Association (AHA/ASA) 2014 guidelines on primary prevention of stroke.

Medical News & Perspectives